4.3 Article

UALCAN: An update to the integrated cancer data analysis platform

Journal

NEOPLASIA
Volume 25, Issue -, Pages 18-27

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.neo.2022.01.001

Keywords

UALCAN; Cancer gene expression; Bioinformatics; Transcriptomics; Patient survival; lncRNA; Proteomics; Correlation; Differential expression

Categories

Funding

  1. UAB Department of Pathology
  2. UAB O'Neal Comprehensive Cancer Center
  3. UAB Heersink School of Medicine
  4. DOD [W81XWH-19-1-0588]
  5. [U54 CA118948]
  6. [CA125123]

Ask authors/readers for more resources

UALCAN is a web portal for exploring, analyzing, and visualizing cancer genomic, transcriptomic, and proteomic data, providing researchers with valuable insights into gene, protein, and pathway alterations in cancer, as well as evaluating patient survival data.
Cancer genomic, transcriptomic, and proteomic profiling has generated extensive data that necessitate the development of tools for its analysis and dissemination. We developed UALCAN to provide a portal for easy exploring, analyzing, and visualizing these data, allowing users to integrate the data to better understand the gene, proteins, and pathways perturbed in cancer and make discoveries. UALCAN web portal enables analyzing and delivering cancer transcriptome, proteomics, and patient survival data to the cancer research community. With data obtained from The Cancer Genome Atlas (TCGA) project, UALCAN has enabled users to evaluate protein-coding gene expression and its impact on patient survival across 33 types of cancers. The web portal has been used extensively since its release and received immense popularity, underlined by its usage from cancer researchers in more than 100 countries. The present manuscript highlights the task we have undertaken and updates that we have made to UALCAN since its release in 2017. Extensive user feedback motivated us to expand the resource by including data on a) microRNAs (miRNAs), long non-coding RNAs (lncRNAs), and promoter DNA methylation from TCGA and b) mass spectrometry-based proteomics from the Clinical Proteomic Tumor Analysis Consortium (CPTAC). UALCAN provides easy access to pre-computed, tumor subgroup-based gene/protein expression, promoter DNA methylation status, and Kaplan-Meier survival analyses. It also provides new visualization features to comprehend and integrate observations and aids in generating hypotheses for testing. UALCAN is accessible at http://ualcan.path.uab.edu

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available